Johnson & Johnson Aktie
WKN: 853260 / ISIN: US4781601046
18.11.2024 13:25:07
|
CHMP Recommends Approval Of Lazcluze + Rybrevant In EU For EGFR-mutated Advanced NSCLC
(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Lazcluze in combination with Rybrevant for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).
The CHMP has simultaneously recommended the approval of a Type II indication extension for amivantamab in the same combination treatment.
The CHMP positive opinions for the approval and the Type II extension of the indication are supported by data from the Phase III MARIPOSA study which evaluated Rybrevant in combination with Lazcluze compared with AstraZeneca's Tagrisso as first-line treatment of patients with EGFR-mutated NSCLC. The study had met its primary endpoint, reducing the risk of disease progression or death by 30 percent compared with Tagrisso. The median progression-free survival was 23.7 months versus 16.6 months for Tagrisso.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
28.07.25 |
Börse New York: Dow Jones präsentiert sich zum Handelsende schwächer (finanzen.at) | |
28.07.25 |
Schwacher Wochentag in New York: Dow Jones gibt zum Start des Montagshandels nach (finanzen.at) | |
25.07.25 |
Börse New York: Dow Jones legt schlussendlich zu (finanzen.at) | |
25.07.25 |
Börse New York: Dow Jones-Anleger greifen zu (finanzen.at) | |
25.07.25 |
Gewinne in New York: Gewinne im Dow Jones (finanzen.at) | |
25.07.25 |
Handel in New York: Dow Jones verbucht zum Start Zuschläge (finanzen.at) | |
23.07.25 |
Mittwochshandel in New York: Dow Jones mittags in Grün (finanzen.at) | |
23.07.25 |
Dow Jones 30 Industrial-Wert Johnson Johnson-Aktie: So viel Gewinn hätte eine Investition in Johnson Johnson von vor 10 Jahren abgeworfen (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 143,12 | -0,06% |
|